Research
Severe Covid-19 linked with molecular signs of brain ageing
Scientists have emphasised the importance of neurological follow-up in patients who have recovered from Covid-19.

Scientists have found similarities between biological pathways in the ageing brain and in patients affected by serve Covid-19 infection.
Although Covid-19 is primarily a respiratory disease, neurological symptoms have been described in many Covid-19 patients, including in recovered individuals.
Patients report symptoms including brain fog or lack of focused thinking, memory loss and depression, and scientists have demonstrated that patients with severe Covid-19 exhibit a drop in cognitive performance that mimics accelerated ageing.
But, the molecular evidence for Covid-19’s ageing effects on the brain is lacking.
In a series of experiments, scientists at Beth Israel Deaconess Medical Center (BIDMC), found that gene usage in the brains of patients with Covid-19 is similar to those observed in ageing brains.
Using a molecular profiling technique called RNA sequencing to measure the levels of every gene expressed in a particular tissue sample, the scientists assessed changes in gene expression profiles in the brains of Covid-19 patients and compared them to those changes observed in the brains of uninfected individuals.
The team’s analysis, published in Nature Aging, suggested that many biological pathways that change with natural ageing in the brain also changed in patients with severe Covid-19.
“Ours is the first study to show that Covid-19 is associated with the molecular signatures of brain ageing,” said co-first and co-corresponding author Maria Mavrikaki, PhD, an instructor of pathology at BIDMC and Harvard Medical School.
“We found striking similarities between the brains of patients with Covid-19 and aged individuals.”
Mavrikaki and colleagues analysed a total of 54 postmortem human frontal cortex tissue samples from adults 22 to 85 years old. Of these, 21 samples were from severe Covid-19 patients and one from an asymptomatic Covid-19 patient who died. These samples were age- and sex-matched to uninfected controls with no history of neurological or psychiatric disease.
The scientists also included an age-and sex- matched uninfected Alzheimer’s disease case for analysis as a control to a Covid-19 case which had co-morbid Alzheimer’s disease, as well as an additional independent control group of uninfected individuals with a history of intensive care or ventilator treatment.
“We observed that gene expression in the brain tissue of patients who died of Covid-19 closely resembled that of uninfected individuals 71-years-old or older,” said co-first author Jonathan Lee, PhD, a postdoctoral research fellow at BIDMC and Harvard Medical School.
“Genes that were upregulated in ageing were upregulated in the context of severe COVID-19; likewise, genes downregulated in ageing were also downregulated in severe Covid-19. While we did not find evidence that the SARS-CoV-2 virus was present in the brain tissue at the time of death, we discovered inflammatory patterns associated with Covid-19. This suggests that this inflammation may contribute to the ageing-like effects observed in the brains of patients with Covid-19 and long covid.”
Senior and co-corresponding author Frank Slack, PhD, director of the Institute for RNA Medicine at BIDMC and the Shields Warren Mallinckrodt Professor of Medical Research at Harvard Medical School, said: “Given these findings, we advocate for neurological follow-up of recovered Covid-19 patients.
“We also emphasise the potential clinical value in modifying the factors associated with the risk of dementia — such as controlling weight and reducing excessive alcohol consumption — to reduce the risk or delay the development of ageing-related neurological pathologies and cognitive decline.”
Better understanding of the molecular mechanisms underlying brain ageing and cognitive decline in Covid-19 could lead to the development of novel therapeutics to address cognitive decline observed in Covid-19 patients.
The team is now trying to understand what drives the ageing-like effects in the brains of Covid-19 patients.
Wellness
Shingles vaccine may slow biological ageing in older adults
News
Blood sugar spike after meals may increase Alzheimer’s risk

Sharp rises in blood sugar after meals may raise Alzheimer’s risk, according to genetic analysis of more than 350,000 adults.
The findings point to after-meal glucose, rather than overall blood sugar, as a possible factor in long-term brain health.
Researchers examined genetic and health data from over 350,000 UK Biobank participants aged 40 to 69, focusing on fasting glucose, insulin, and blood sugar measured two hours after eating.
The team used Mendelian randomisation, a genetic method that helps test whether biological traits may play a direct role in disease risk.
People with higher after-meal glucose had a 69 per cent higher risk of Alzheimer’s disease.
This pattern, known as postprandial hyperglycaemia (elevated blood sugar after eating), stood out as a key factor.
The increased risk was not explained by overall brain shrinkage (atrophy) or white matter damage, suggesting after-meal glucose may affect the brain through other pathways not yet fully understood.
Dr Andrew Mason, lead author, said: “This finding could help shape future prevention strategies, highlighting the importance of managing blood sugar not just overall, but specifically after meals.”
Dr Vicky Garfield, senior author, added: “We first need to replicate these results in other populations and ancestries to confirm the link and better understand the underlying biology.
“If validated, the study could pave the way for new approaches to reduce dementia risk in people with diabetes.”
Insights
Study reveals why memory declines with age

A recent international study that pooled brain scans and memory tests from thousands of adults has shed new light on how structural brain changes are tied to memory decline as people age.
The findings show that the connection between shrinking brain tissue and declining memory is nonlinear, stronger in older adults, and not solely driven by known Alzheimer’s-associated genes like APOE ε4.
This suggests that brain ageing is more complex than previously thought, and that memory vulnerability reflects broad structural changes across multiple regions, not just isolated pathology.
Alvaro Pascual-Leone, MD, PhD is senior scientist at the Hinda and Arthur Marcus Institute for Aging Research and medical director at the Deanna and Sidney Wolk Center for Memory Health.
The researcher said: “By integrating data across dozens of research cohorts, we now have the most detailed picture yet of how structural changes in the brain unfold with age and how they relate to memory.”
The study found that structural brain change associated with memory decline is widespread, rather than confined to a single region.
While the hippocampus showed the strongest association between volume loss and declining memory performance, many other cortical and subcortical regions also demonstrated significant relationships.
This suggests that cognitive decline in ageing reflects a distributed macrostructural brain vulnerability, rather than deterioration in a few specific brain regions.
The pattern across regions formed a gradient, with the hippocampus at the high end and progressively smaller but still meaningful effects across large portions of the brain.
Importantly, the relationship between regional brain atrophy and memory decline was not only variable across individuals but also highly nonlinear.
Individuals with above-average rates of structural loss experienced disproportionately greater declines in memory, suggesting that once brain shrinkage reaches higher levels, cognitive consequences accelerate rather than progress evenly.
This nonlinear pattern was consistent across multiple brain regions, reinforcing the conclusion that memory decline in cognitively healthy ageing is linked to global and network-level structural changes, with the hippocampus playing a particularly sensitive role but not acting alone.
Pascual-Leone said: “Cognitive decline and memory loss are not simply the consequence of ageing, but manifestations of individual predispositions and age-related processes enabling neurodegenerative processes and diseases.
“These results suggest that memory decline in ageing is not just about one region or one gene — it reflects a broad biological vulnerability in brain structure that accumulates over decades.
“Understanding this can help researchers identify individuals at risk early, and develop more precise and personalized interventions that support cognitive health across the lifespan and prevent cognitive disability.”
News2 weeks agoFDA clears automated brain fluid device
News2 weeks agoAgetech World’s latest innovation & investment round-up
Markets & Industry2 weeks agoInsilico signs US$888m oncology deal with Servier
News2 weeks agoFood preservatives linked to increased diabetes and cancer risk, study finds
News2 weeks agoUK bans junk food ads before 9pm to protect child health
News1 week agoCaptioning glasses win AARP pitch at CES
Insights2 weeks agoGlobal longevity initiative launches North American chapter
Research6 days agoInterview: GlycanAge launch first hospital-based tests





















